Cargando…
Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model
BACKGROUND: There are a few nutritional approaches to address the increased needs of managing diabetic conditions. Previously it has been reported that UP780, a standardized composition of aloe chromone formulated with an aloe polysaccharide, has a significant impact in reducing HbA1C, fasting blood...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041641/ https://www.ncbi.nlm.nih.gov/pubmed/24891878 http://dx.doi.org/10.1186/1758-5996-6-61 |
_version_ | 1782318699513905152 |
---|---|
author | Yimam, Mesfin Zhao, Jifu Corneliusen, Brandon Pantier, Mandee Brownell, Lidia Jia, Qi |
author_facet | Yimam, Mesfin Zhao, Jifu Corneliusen, Brandon Pantier, Mandee Brownell, Lidia Jia, Qi |
author_sort | Yimam, Mesfin |
collection | PubMed |
description | BACKGROUND: There are a few nutritional approaches to address the increased needs of managing diabetic conditions. Previously it has been reported that UP780, a standardized composition of aloe chromone formulated with an aloe polysaccharide, has a significant impact in reducing HbA1C, fasting blood glucose, fructosamine and plasma insulin level in humans and improved impaired glucose and insulin resistance in high-fat diet-induced and db/db non-insulin dependent diabetic mouse models. Here we describe activity of UP780 and its constituents to improve insulin sensitivity in alloxan induced insulin dependent diabetic mouse model. MATERIALS AND METHOD: Insulin dependent diabetes was induced by administering a single intraperitoneal injection of alloxan monohydrate at a dose of 150 mg/kg to CD-1 mice. Aloesin (UP394) was formulated with an Aloe vera inner leaf gel powder polysaccharide (Qmatrix) to yield a composition designated UP780. Efficacy of oral administration of UP780 at 2000 mg/kg and its constituents (aloesin at 80 mg/kg and Qmatrix at 1920 mg/kg) were evaluated in this model. Glyburide, a sulfonylurea drug used in the treatment of type 2 diabetes, was used at 5 mg/kg as a positive control. Effect of UP780 on non-diabetic normal mice was also addressed. RESULTS: Mice administered intraperitoneal alloxan monohydrate developed progressive type-1 diabetes like symptom. After 4 weeks of daily oral administration, reductions of 35.9%, 17.2% and 11.6% in fasting blood glucose levels were observed for UP780, the UP780 Aloe vera inner leaf gel polysaccharide preparation without chromone (Qmatrix), and Aloesin (UP394), treated animals respectively, compared to vehicle treated animals. UP780 has no impact on blood glucose level of non-diabetic healthy mice. UP780 showed statistically significant improvement for blood glucose clearance in oral glucose tolerance tests. Similarly, enhanced improvement in plasma insulin level and statistically significant reduction in triglyceride level was also observed for animals treated with the composition. CONCLUSION: These findings suggest that UP780, a chromone standardized Aloe based composition, could possibly be used as a natural supplement alternative to facilitate maintenance of healthy blood glucose levels. |
format | Online Article Text |
id | pubmed-4041641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40416412014-06-03 Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model Yimam, Mesfin Zhao, Jifu Corneliusen, Brandon Pantier, Mandee Brownell, Lidia Jia, Qi Diabetol Metab Syndr Research BACKGROUND: There are a few nutritional approaches to address the increased needs of managing diabetic conditions. Previously it has been reported that UP780, a standardized composition of aloe chromone formulated with an aloe polysaccharide, has a significant impact in reducing HbA1C, fasting blood glucose, fructosamine and plasma insulin level in humans and improved impaired glucose and insulin resistance in high-fat diet-induced and db/db non-insulin dependent diabetic mouse models. Here we describe activity of UP780 and its constituents to improve insulin sensitivity in alloxan induced insulin dependent diabetic mouse model. MATERIALS AND METHOD: Insulin dependent diabetes was induced by administering a single intraperitoneal injection of alloxan monohydrate at a dose of 150 mg/kg to CD-1 mice. Aloesin (UP394) was formulated with an Aloe vera inner leaf gel powder polysaccharide (Qmatrix) to yield a composition designated UP780. Efficacy of oral administration of UP780 at 2000 mg/kg and its constituents (aloesin at 80 mg/kg and Qmatrix at 1920 mg/kg) were evaluated in this model. Glyburide, a sulfonylurea drug used in the treatment of type 2 diabetes, was used at 5 mg/kg as a positive control. Effect of UP780 on non-diabetic normal mice was also addressed. RESULTS: Mice administered intraperitoneal alloxan monohydrate developed progressive type-1 diabetes like symptom. After 4 weeks of daily oral administration, reductions of 35.9%, 17.2% and 11.6% in fasting blood glucose levels were observed for UP780, the UP780 Aloe vera inner leaf gel polysaccharide preparation without chromone (Qmatrix), and Aloesin (UP394), treated animals respectively, compared to vehicle treated animals. UP780 has no impact on blood glucose level of non-diabetic healthy mice. UP780 showed statistically significant improvement for blood glucose clearance in oral glucose tolerance tests. Similarly, enhanced improvement in plasma insulin level and statistically significant reduction in triglyceride level was also observed for animals treated with the composition. CONCLUSION: These findings suggest that UP780, a chromone standardized Aloe based composition, could possibly be used as a natural supplement alternative to facilitate maintenance of healthy blood glucose levels. BioMed Central 2014-05-24 /pmc/articles/PMC4041641/ /pubmed/24891878 http://dx.doi.org/10.1186/1758-5996-6-61 Text en Copyright © 2014 Yimam et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Yimam, Mesfin Zhao, Jifu Corneliusen, Brandon Pantier, Mandee Brownell, Lidia Jia, Qi Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model |
title | Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model |
title_full | Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model |
title_fullStr | Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model |
title_full_unstemmed | Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model |
title_short | Blood glucose lowering activity of aloe based composition, UP780, in alloxan induced insulin dependent mouse diabetes model |
title_sort | blood glucose lowering activity of aloe based composition, up780, in alloxan induced insulin dependent mouse diabetes model |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041641/ https://www.ncbi.nlm.nih.gov/pubmed/24891878 http://dx.doi.org/10.1186/1758-5996-6-61 |
work_keys_str_mv | AT yimammesfin bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel AT zhaojifu bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel AT corneliusenbrandon bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel AT pantiermandee bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel AT brownelllidia bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel AT jiaqi bloodglucoseloweringactivityofaloebasedcompositionup780inalloxaninducedinsulindependentmousediabetesmodel |